Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
ipo
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
vc
venture capital
wisconsin blog main
wisconsin top stories
2025
accent therapeutics
ad-comm
aducanumab
affimed
akcea therapeutics
allogene therapeutics
What
bio
3
×
ipo
3
×
new
3
×
medicines
million
roundup
activity
allogene
analysis
approvals
biogen
biotech
bring
cancer
clamped
company
covid
crispr
delays
develop
developing
diseases
diversity
drug
economic
employing
fast
fda
genetic
goldfinch
hot
immunotherapy
including
investors
isn’t
juno
kidney
later
lead
lot
Language
unset
Current search:
ipo
×
new
×
bio
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More